Alize reports Phase II Prader-Willi data

Alize Pharma S.A.S. (Lyon, France) said once-daily subcutaneous AZP-531 for two weeks led to significant improvements in hyperphagia-related behavior vs. placebo in a European Phase II trial to treat Prader-Willi syndrome. The unacylated ghrelin analog significantly improved patient scores on the Hyperphagia Questionnaire vs. placebo (p<0.05).

The company said AZP-531-treated patients had a significant reduction in appetite following breakfast, a patient-reported outcome, vs. baseline (p<0.001), while the placebo group did not. Patients receiving the candidate also had a significant reduction in waist circumference vs. baseline (p<0.05), while placebo-treated patients did not. Neither group had a significant change in body weight. ...